Artificial Lipid Membrane Permeability Method for Predicting Intestinal Drug Transport: Probing the Determining Step in the Oral Absorption of Sulfadiazine; Influence of the Formation of Binary and Ternary Complexes with Cyclodextrins
- 109 Downloads
We propose an in vitro permeability assay by using a modified lipid membrane to predict the in vivo intestinal passive permeability of drugs. Two conditions were tested, one with a gradient pH (pH 5.5 donor/pH 7.4 receptor) and the other with an iso-pH 7.4. The predictability of the method was established by correlating the obtained apparent intestinal permeability coefficients (Papp) and the oral dose fraction absorbed in humans (fa) of 16 drugs with different absorption properties. The Papp values correlated well with the absorption rates under the two conditions, and the method showed high predictability and good reproducibility. On the other hand, with this method, we successfully predicted the transport characteristics of oral sulfadiazine (SDZ). Also, the tradeoff between the increase in the solubility of SDZ by its complex formation with cyclodextrins and/or aminoacids and its oral permeability was assessed. Results suggest that SDZ is transported through the gastrointestinal epithelium by passive diffusion in a pH-dependent manner. These results support the classification of SDZ as a high/low borderline permeability compound and are in agreement with the Biopharmaceutics Classification Systems (BCS). This conclusion is consistent with the in vivo pharmacokinetic properties of SDZ.
Key Wordssulfadiazine β-cyclodextrin aminoacids binary and ternary complexes in vitro permeability method intestinal absorption of sulfadiazine
The authors wish to acknowledge the assistance of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), the Secretaría de Ciencia y Técnica de la Universidad Nacional de Córdoba (SECyT-UNC), and Fondo para la Investigación Científica y Tecnológica (FONCYT) which provided support and facilities for this investigation. We also thank Ferromet S.A. (agent of Roquette in Argentina) for their donation of cyclodextrins and DROMEX SA Argentina for the gift of Lipoid 75.
- 6.Bujard A, Petit C, Carrupt P-A, Rudaz S, Schappler J. HDM-PAMPA to predict gastrointestinal absorption, binding percentage, equilibrium and kinetics constants with human serum albumin and using 2 end-point measurements. Eur J Pharm Sci. 2017;97:143–50. https://doi.org/10.1016/j.ejps.2016.11.001.CrossRefPubMedGoogle Scholar
- 7.Stewart AM, Grass ME, Mudie DM, Morgen MM, Friesen DT, Vodak DT. Development of a biorelevant, material-sparing membrane flux test for rapid screening of bioavailability-enhancing drug product formulations. Mol Pharm. 2017;14(6):2032–46. https://doi.org/10.1021/acs.molpharmaceut.7b00121.CrossRefPubMedGoogle Scholar
- 9.Tsinman O, Tsinman K, Sun N, Avdeef A. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res. 2011;28(2):337–63. https://doi.org/10.1007/s11095-010-0280-x.CrossRefPubMedGoogle Scholar
- 12.Bhardwaj R, Chandrasena G Optimal ADME properties for clinical candidate and investigational new drug (IND) package. In: Zhang D, Surapaneni S editors ADME-enabling technologies in drug design and development New Jersey: John Wiley & Sons, Hoboken; 2012. p. 15–28, DOI: https://doi.org/10.1002/9781118180778.ch2.
- 19.Delrivo A, Zoppi A, Granero G, Longhi M. Studies of ternary systems of sulfadiazine with β-cyclodextrin and aminoacids. Ars Pharm. 2016;57(4):167–76.Google Scholar
- 21.CDER/FDA, U. S. (2000). Guidances for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.Google Scholar
- 22.Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an insitu perfusion model for permeability determinations: utility for BCS Class I biowaiver requests. Mol Pharm 2006;3:686–694.Google Scholar
- 23.Varma MV, Gardner I, Steyn J, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KD, El-Kattan AF. pH-dependent solubility and permeability criteria for provisional Biopharmaceutics Classification (BCS and BDDCS) in early drug discovery. Mol Pharm 2012;9:1199–1212.Google Scholar
- 24.Kotecha J, Sha S, Rathod I, Subbaiah IR. Prediction of oral absorption in humans by experimental immobilized artificial membrane chromatography indices and physicochemical descriptors. Int J Pharm 2008;360:96–106.Google Scholar
- 25.Larregieu CA, Benet LZ. Distinguishing between the permeability relationship with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm. 2014;11(4):1335–44. https://doi.org/10.1021/mp4007858.
- 26.Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm 2001;228:181–8.Google Scholar
- 27.Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evalueation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci 2006;27:354–362.Google Scholar
- 28.Tam KY, Avdeef A, Tsinman O, Sun N. The permeation of amphoteric drugs through artificial membranes – An in combo absorption model based on paracellular and transmembrane permeability. J Med Chem 2010;53:392–401.Google Scholar
- 30.Flanagan SD, Takahashi LH, Liu X, Benet LZ. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci. 2002;91(4):1169–77. https://doi.org/10.1002/jps.10099.CrossRefPubMedGoogle Scholar
- 35.Van Petten GR, Becking GC, Withey RJ, Lettau F. Studies on the physiological availability and metabolism of sulfonamides. I. sulfadiazine. J Clin Pharmacolog. 1971;11:27–34.Google Scholar
- 37.Vree TB, de Ven ES, Verwey-van W, et al. Isolation, identification and determination of sulfadiazine and its hydroxy metabolites and conjugates from man and Rhesus monkey by high-performance liquid chromatography. J Chromatograph B: Biomed Sci Applic. 1995;670(1):111–23. https://doi.org/10.1016/0378-4347(95)00163-D.CrossRefGoogle Scholar
- 40.Fine-Shamir N, Beig A, Zur M, Lindley D, Miller JM, Dahan A. Toward successful cyclodextrin based solubility-enabling formulations for oral delivery of lipophilic drugs: solubility-permeability trade-off, biorelevant dissolution, and the unstirred water layer. Mol Pharm. 2017;14(6):2138–46. https://doi.org/10.1021/acs.molpharmaceut.7b00275.CrossRefPubMedGoogle Scholar